Jump to content
  • Message from the Founder - Volunteers and Transparency

    foundermessage.pngbrady_tn.jpgrrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    In January 2005 the Board of Directors chose me as the director of the RRDi, and Warren Stuart as the Assistant Director. In 2010 we were again voted to serve another five years on the board. Same for 2015 and in 2020. The board decided to make me the treasurer in 2020. 

    Warren was instrumental in forming and establishing the RRDi, helping out with our web site and setting up our member forum. Warren also established a sister site relationship with his Rosacea Forum. Sadly, Warren passed away in 2012 (for more info click here).

    You might be interested in a more detailed history of the RRDi

    An article was written on why I formed the RRDi. You should carefully investigate the other non profit organizations for rosacea and compare how they are run with the RRDi. The big difference is that this non profit is run with a volunteer spirit by rosacea sufferers, a grassroots, patient advocacy effort. The other non profit organizations for rosacea are run by non rosaceans who are businessmen and dermatologists. 


    Volunteers
    This is the driving force behind this non profit organization for rosacea founded by rosacea sufferers. For more information

    Spending
    The one thing you can be sure of is that any donations will NOT be spent on private contractors or salaries at this point since everyone associated with the RRDi are volunteers. This can be done because of the volunteer spirit with which this institute was set up. Can you help? When you join, in the comment box let us know you want to volunteer. If you simply join that would increase our numbers. Any small donation helps us keep going. However, volunteering is what makes this non profit different from the other rosacea non profits (read this post). 

    Research
    A database of research suggestions is being accumulated which you may access or make suggestions by clicking here.

    Who Serves on the Board of Directors
    The RRDi is the only non profit that allows rosaceans any say in determining who is on the board of directors. The other non profits are closed board of directors and if you aren't happy with the direction there is nothing you can do about it. Whatever the direction the RRDi takes, whether to research the cause, or the cure, or whatever is done you can at least know that rosaceans had a say into what research the RRDi will engage in. While the board of directors have the final say on this, you can change who serves on the board of directors who are all rosacea sufferers. Try doing this with the other non profit organizations for rosacea. 

    Transparency
    We believe in transparency. How the RRDi is run is public knowledge. You can clearly review all our financial records. All the other non profits keep their articles of incorporation a deep secret. Their financial records are cryptically revealed in only an IRS Form 990 report that is confusing and difficult to read. That is a big difference. You have a say if you join and become a corporate member. You can vote who is on the board of directors. Can you do that with any other rosacea non profit organization? I have always felt that rosaceans should have a say in what is being done and not leave that up totally to those who may have their own agenda or leave the decision to private contractors. The MAC at the RRDi is just that; a medical ADVISORY committee. The board of directors who are rosaceans make the final decision on the research and all matters. And if you desire, you as a rosacean, if you join the RRDi as a corporate member, can determine who serves on the board of directors.

    Non Profit Organization
    501 (c) (3) tax-exempt status has been approved by the IRS effective June 7, 2004. This means your donation is tax deductible. With such a legacy, you can see the RRDi is a solid non profit organization for rosaceans you can trust. Please join

    Brady Barrows
    RRDi Founder

     



  • Forum Statistics

    • Total Topics
      6.1k
    • Total Posts
      7.9k
  • Posts

    • Dermatologie (Heidelb). 2023 Mar 7. doi: 10.1007/s00105-023-05123-8. Online ahead of print. ABSTRACT Dermoscopy is an easily accessible, noninvasive diagnostic tool, originally used in the differentiation of benign and malignant skin tumors. Other structures beside pigment content observed by dermoscopy, e.g., scaling, follicles, or vessels, may present in a specific pattern in different dermatoses. Recognition of these patterns may aid the diagnosis of inflammatory and infectious dermatological conditions. The aim of this article is to review the distinct dermoscopic features of granulomatous and autoimmune skin diseases. Diagnosis of granulomatous skin disorders is based on the histopathological examination. The dermoscopic picture of these diseases (cutaneous sarcoidosis, granuloma annulare, necrobiosis lipoidica, and granulomatous rosacea) show many similarities; however, there are some differences to note between the dermatoses, mainly in granuloma annulare. The cornerstones of the diagnostic process of autoimmune skin diseases (morphea, systemic sclerosis, dermatomyositis, cutaneous lupus erythematosus) include the clinical picture, immunoserology, and histology; however, dermoscopy may aid the diagnostic process and follow-up of the patients. For those diseases, where vascular abnormalities play an important role in the pathogenesis, videocapillaroscopy is used for examination of the microcirculation at the nailfold capillaries. Dermoscopy can be an easy-to-use everyday diagnostic tool in clinical practice regarding granulomatous and autoimmune skin diseases. Although punch biopsy is inevitable in many cases, the distinct dermoscopic structures can aid the diagnostic process. PMID:36881125 | DOI:10.1007/s00105-023-05123-8 {url} = URL to article
    • Front Pharmacol. 2023 Feb 15;14:1037925. doi: 10.3389/fphar.2023.1037925. eCollection 2023. ABSTRACT TRPV1 is a non-selective channel receptor widely expressed in skin tissues, including keratinocytes, peripheral sensory nerve fibers and immune cells. It is activated by a variety of exogenous or endogenous inflammatory mediators, triggering neuropeptide release and neurogenic inflammatory response. Previous studies have shown that TRPV1 is closely related to the occurrence and/or development of skin aging and various chronic inflammatory skin diseases, such as psoriasis, atopic dermatitis, rosacea, herpes zoster, allergic contact dermatitis and prurigo nodularis. This review summarizes the structure of the TRPV1 channel and discusses the expression of TRPV1 in the skin as well as its role of TRPV1 in skin aging and inflammatory skin diseases. PMID:36874007 | PMC:PMC9975512 | DOI:10.3389/fphar.2023.1037925 {url} = URL to article
    • Indian J Dermatol. 2022 Sep-Oct;67(5):625. doi: 10.4103/ijd.ijd_353_21. ABSTRACT BACKGROUND: Thirty per cent supramolecular salicylic acid (SSA) is a water-soluble, sustained release salicylic acid (SA) modality, which is well tolerated by sensitive skin. Anti-inflammatory therapy plays an important role in papulopustular rosacea (PPR) treatment. SSA at a 30% concentration has a natural antiinflammatory property. AIMS: This study aims to investigate the efficacy and safety of 30% SSA peeling for PPR treatment. METHODS: Sixty PPR patients were randomly divided into two groups: SSA group (30 cases) and control group (30 cases). Patients of the SSA group were treated with 30% SSA peeling three times every 3 weeks. Patients in both groups were instructed to topically apply 0.75% metronidazole gel twice daily. Transdermal water loss (TEWL), skin hydration and erythema index were assessed after 9 weeks. RESULTS: Fifty-eight patients completed the study. The improvement of erythema index in the SSA group was significantly better than that in the control group. No significant difference was found in terms of TEWL between the two groups. The content of skin hydration in both the groups increased, but there was no statistical significance. No severe adverse events were observed in both the groups. CONCLUSION: SSA can significantly improve the erythema index and overall appearance of skin in rosacea patients. It has a good therapeutic effect, good tolerance and high safety. PMID:36865859 | PMC:PMC9971792 | DOI:10.4103/ijd.ijd_353_21 {url} = URL to article
    • Medicine (Baltimore). 2023 Mar 3;102(9):e33023. doi: 10.1097/MD.0000000000033023. ABSTRACT Rosacea is a chronic erythematous disease with telangiectasia that affects the central area of the face. However, because of the ambiguity in the pathophysiology of rosacea, its treatment has not been clearly elucidated; therefore, new therapeutic options need to be developed. Gyejibokryeong-hwan (GBH) is widely used in clinical practice for various blood circulation disorders, including hot flushes. Therefore, we explored the potential pharmaceutical mechanism of GBH on rosacea and investigated the therapeutic points exclusive to GBH through comparative analysis with chemical drugs recommended in 4 guidelines for rosacea based on network analysis. The active compounds in GBH were identified, and the proteins targeted by these compounds and the genes related to rosacea were searched. Additionally, the proteins targeted by the guideline drugs were also searched to compare their effects. And the pathway/term analysis of common genes was conducted. Ten active compounds were obtained for rosacea. There were 14 rosacea-related genes targeted by GBH, with VEGFA, TNF, and IL-4, which were suggested as core genes. The pathway/term analysis of the 14 common genes revealed that GBH could potentially act on rosacea via 2 pathways: the "interleukin 17 signaling pathway" and the "neuroinflammatory response." Comparison and analysis of the protein targets between GBH and guideline drugs revealed that only GBH separately acts on the "vascular wound healing pathway." GBH has the potential to act on IL-17 signaling pathway, neuroinflammatory response and vascular wound healing pathway. Further studies are needed to determine the potential mechanism of GBH in rosacea. PMID:36862896 | PMC:PMC9981404 | DOI:10.1097/MD.0000000000033023 {url} = URL to article
    • Eur J Dermatol. 2022 Nov 1;32(6):716-723. doi: 10.1684/ejd.2022.4358. ABSTRACT BACKGROUND: Contact hypersensitivity or Demodex mite infestation is commonly reported in patients with rosacea. However, the associations and clinical implications of these two phenomena are poorly described in the literature. OBJECTIVES: This study aimed to investigate the association between clinical characteristics, contact sensitization profiles, and Demodex mite infestation in patients with rosacea. MATERIALS & METHODS: We retrospectively reviewed 189 patients diagnosed with rosacea, and categorized the patients into a rosacea-contact hypersensitivity or rosacea-non-contact hypersensitivity group. RESULTS: The rosaceacontact hypersensitivity group had older age (median: 45.5 vs. 37.0 years; p = 0.006), a higher frequency of itching (63.0% vs. 45.1%; p = 0.040), and a higher Demodex mite density (15.0/cm2 vs. 7.0/cm2; p = 0.002) than the rosacea-non-contact hypersensitivity group. Nickel sensitization was correlated with a higher Demodex mite density, female sex, and papulopustular subtype of rosacea. Based on the multivariate regression model, a favourable clinical outcome was correlated with nickel sensitization alone (odds ratio: 2.20, 95% confidence interval: 1.01-4.81). CONCLUSION: Patients with rosacea and contact hypersensitivity showed distinctive clinical features and a higher Demodex mite density. The association between nickel sensitization, Demodex mite infestation, and treatment response may reflect the role of allergen-specific TH polarization in the pathogenesis of rosacea. PMID:36856381 | DOI:10.1684/ejd.2022.4358 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use